Attach to paper no 4

FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Attorney Docket No.: AVIGEN.003C1	Serial No.: Unknown
Applicant: Linda B. Couto *et al.*	
Filing Date: Herewith	Group Art Unit: ~~Unknown~~ 1635

09/740211 12/18/00

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
PL	1	4,757,006	Jul. 12, 1988	Toole, Jr. *et al.*			Oct. 28, 1983
	2	4,886,876	Dec. 12, 1989	Zimmerman *et al.*			Apr. 13, 1987
	3	5,004,803	Apr. 2, 1991	Kaufman *et al.*			Nov. 14, 1988
	4	5,045,455	Sept. 3, 1991	Kuo *et al.*			June 14, 1990
	5	5,112,950	May 12, 1992	Meulien *et al.*			June 26, 1991
	6	5,139,941	Aug. 18, 1992	Muzyczka *et al.*			Oct. 25, 1991
	7	5,149,637	Sept. 22, 1992	Scandella *et al.*			Sept. 20, 1990
	8	5,171,844	Dec. 15, 1992	van Ooyen *et al.*			June 10, 1988
	9	5,173,414	Dec. 22, 1992	Lebkowski *et al.*			Oct. 30, 1990
	10	5,422,260	June 6, 1995	Kaufman *et al.*			May 15, 1992
	11	5,451,521	Sept. 19, 1995	Kaufman *et al.*			Dec. 9, 1986
	12	5,595,886	Jan. 21, 1997	Chapman *et al.*			Dec. 3, 1993
	13	5,563,045	Oct. 8, 1996	Pittman *et al.*			Sept. 14, 1993
	14	5,587,310	Dec. 24, 1996	Kane *et al.*			July 11, 1994
	15	5,622,856	Apr. 22, 1997	Natsoulis			Aug. 3, 1995
	16	5,633,150	May 27, 1997	Wood *et al.*			Oct. 9, 1990
	17	5,661,008	Aut. 26, 1997	Almstedt *et al.*			Jun. 5, 1995
	18	5,668,108	Sept. 16, 1997	Capon *et al.*			May 23, 1995
	19	5,681,746	Oct. 28, 1997	Bodner *et al.*			Dec. 30, 1994
	20	5,693,499	Dec. 2, 1997	Yonemura *et al.*			Jul. 18, 1994
	21	5,720,720	Feb. 24, 1998	Laske *et al.*			Mar. 15, 1996
	22	5,789,203	Aug. 4, 1998	Chapman *et al.*			Jun. 27, 1994
	23	5,858,351	Jan. 12, 1999	Podsakoff *et al.*			Jan. 18, 1996
PL	24	5,846,528	Dec. 8, 1998	Podsakoff *et al.*			Jan. 16, 1997

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation Yes	Translation No
PL	25	WO 87/07144	Dec. 3, 1987	~~PCT~~ WIPO				
	26	WO 91/07490	May 30, 1991	PCT				
	27	WO 91/09122	June 27, 1991	PCT				
	28	WO 92/01070	Jan. 23, 1992	PCT				
	29	WO 92/08981	May 29, 1992	PCT				
	30	WO 92/16557	Oct. 1, 1992	PCT				
PL	31	WO 93/03367	Feb. 18, 1993	PCT WIPO				

Examiner: Brian N. Attorney

Date Considered: 1/9/03

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN.003C1	Serial No.: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Linda B. Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

DW	32	WO 93/03769	Mar. 4, 1993	PCT WIPO
	33	WO 94/11503	May 26, 1994	PCT
	34	WO 96/21035	July 11, 1996	PCT
	35	WO 97/03195	Jan. 30, 1997	PCT WIPO
	36	EP 0 160 457	Jan. 16, 1991	EP
	37	EP 0 162 067	July 15, 1992	EP
	38	EP 0 182 448	May 28, 1986	EP
	39	EP 0 220 618	Oct. 16, 1986	EP
	40	EP 0 232 112	Dec. 1, 1993	EP
	41	EP 0 500 734	Feb. 11, 1998	EP
	42	EP 0 506 757	Aug. 26, 1998	EP
	43	EP 0 533 862	Oct. 27, 1999	EP
	44	EP 0 670 332	Sept. 6, 1995	EP
	45	EP 0 672 138	Sept. 20, 1995	EP
	46	EP 0 786 474	July 30, 1997	EP
	47	EP 0 795 021	Sept. 17, 1997	EP
DW	48	EP 0 874 057	Oct. 28, 1998	EP

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

DW	49	Aiello *et al.*, "Adenovirus 5 DNA Sequences Present and RNA Sequences Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293) *Virol.*, 94:460-469 (1979);
	60	Antonarakis *et al.*, "Molecular Genetics of Hemophilia A in Man (Factor VIII Deficiency)," *Mol. Biol. Med.*, 4:81-94 (1987)
	51	Berns, "Parvoviridae and Their Replication," *in* Fields and Knipes (eds.), *Fundamental Virology*, 2nd Edition, pp. 817-837 (1991);
	52	Boshart *et al.*, "A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus," *Cell* 41:521-530 (1985);
	53	Buller *et al.*, "Herpes Simplex Virus Types 1 and 2 Completely Help Adenovirus-Associated Virus Replication," *J. Virol.*, 40:241-247 (1981)
	54	Capecchi, "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," *Cell* 22:479-488 (1980);
	55	Carter, "Adeno-Associated Virus Helper Functions," in *CRC Handbook of Parvoviruses*, Vol. I (P. Tijssen, ed.), pp. 533-539 (1990);
	56	Carter, "Adeno-associated virus vectors," *Curr. Opin. Biol.*, 3:533-539 (1992);
	57	Chu *et al.*, "SV40 DNA transfection of cells in suspension: analysis of the efficiency of transcription and translation of T-antigen," *Gene* 13:197-202 (1981);
	58	Costa and Grayson, "Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region," *Nucl. Acids. Res.*, 19:4139-4145 (1991)
	59	Costa *et al.*, "Transcriptional Control of the Mouse Prealbumin (Transthyretin) Gene: Both Promoter Sequences and a Distinct Enhancer Are Cell Specific," *Mol. Cell. Biol.*, 6:4697 (1986)
	60	Davis *et al.*, *Basic Methods in Molecular Biology*, Elsevier (1986) (Title and Copyright Pages Only);
	61	Dijkema *et al.*, "Cloning and expression of the chromosomal immune interferon gene of the rat," *EMBO J.* 4:761-767 (1985);
DW	62	Edge, "Total Synthesis Of A Human Leukocyte Interferon Gene", *Nature* 292:756-761(1981);

Examiner: [signature] Date Considered: 9/10/01 1/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN.0031	Serial No.: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Linda B. Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

BV	63	Felgner *et al.*, "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," *Proc. Natl. Acad. Sci. U.S.A.* 84: 7413-7417 (1987);
	64	Ganz *et al.*, "Human factor VIII from heparinized plasma: purification and characterization of a single-chain form," *Eur. J. Biochem.*, 170:521-528 (1988);
	65	Glover *et al.* (ed.), *DNA Cloning: A Practical Approach,* vols. I and II, Oxford; New York: IRL Press (1995) (Title and Copyright Pages Only)
	66	Gorman *et al.*, "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," *Proc. Natl. Acad. Sci. USA* 79: 6777-6781 (1982);
	67	Graham and van der Eb, "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA," *Virol.*, 52: 456-467 (1973);
	68	Graham *et al.*, "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," *J. Gen. Virol.*, 36:59-72 (1977);
	69	Herzog *et al.*, "Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector," *Nature Med.*, 5:56-63 (1999);
	70	Janik *et al.*, "Locations of adenovirus genes required for the replication of adenovirus-associated virus," *Proc. Natl. Acad. Sci. USA* 78:1925-1929 (1981);
	71	Jay *et al.*, "Chemical Synthesis Of A Biologically Active Gene For Human Immune Interferon-γ," *J. Biol. Chem.* 259:6311-6317 (1984);
	72	Kaufman *et al.*, "Synthesis, Processing, and Secretion of Recombinant Human Factor VII Expressed in Mammalian Cells," *J. Biol. Chem.*, 263:6352-6362 (1988);
	73	Kaufman, "Biological Regulation of Factor VIII Activity," *Ann. Rev. Med.*, 43:325-339 (1992);
	74	Kim *et al.*, "Use of the human elongation factor 1α promoter as a versatile and efficient expression system," *Gene* 91:217-223 (1990);
	75	Klein *et al.*, "High-velocity microprojectives for delivering nucleic acids into living cells," *Nature* 327:70-73 (1987);
	76	Kotin, "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy," *Hum. Gen. Ther.*, 5:793-801 (1994);
	77	Lebkowski *et al.*, "Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types," *Mol. Cell. Biol.*, 8:3988-3996 (1988);
	78	Lind *et al.*, "Novel forms of B-domain-deleted recombinant factor VIII molecules: construction and biochemical characterization," *Eur. J. Biochem.*, 232:19-27 (1995);
	79	Maniatis *et al.*, "Regulation of Inducible and Tissue-Specific Gene Expression," *Science* 236: 1237-1244 (1987);
	80	Mannino *et al.*, "Liposome Mediated Gene Transfer," *BioTechn.*, 6:682-690 (1988);
	81	Matsushita *et al.*, "Adeno-associated virus vectors can be efficiently produced without helper virus," *Gene Ther.*, 5:938-945 (1998);
	82	McCarty *et al.*, "Sequences Required for Coordinate Induction of Adeno-Associated Virus p19 and p40 Promoters by Rep Protein," *J. Virol.*, 65:2936-2945 (1991);
	83	McPherson *et al.*, "Human Cytomegalovirus Completely Helps Adeno-Associated Virus Replication," *Virol.*, 147:217-222 (1985);
	84	Mizushima and Nagata, "pEF-BOS, a powerful mammalian expression vector," *Nucl. Acids. Res.*, 18:5322 (1990);
	85	Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," *Curr. Top. Microbiol. Immunol.*, 158:97-129 (1992);
	86	Nakai *et al.*, *Blood* 91:1-9 (1998); **Reference could not be otbained at this time. Will provide a copy at a later date should the Examiner desire a copy.**
	87	Nambair *et al.*, "Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S Protein," *Science* 223:1299-1301 [1984];
	88	*Remington's Pharmaceutical Sciences* 18th ed., Easton, Pa: Mack Pub. Co. [1990]; **Reference could not be otbained at this time. Will provide a copy of the Title and Copyright pages at a later date should the Examiner desire a copy.**
	89	Samadani *et al.*, "Identification of a Transthyretin Enhancer Site That Selectively Binds the Hepatocyte Nuclear Factor-3β Isoform," *Gene Expression* 6:23-33 (1996);
BV	90	Sambrook *et al.*, *Molecular Cloning, a Laboratory Manual*, Cold Spring Harbor Laboratories, New York (1989) (Title and Copyright Pages Only);

Examiner: Brian McMillan	Date Considered: 1/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN.003C1	Serial No. Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Linda B. Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

BL	91	Samulski *et al.*, "Helper-Free Stocks Of Recombinant Adeno-Associated Viruses: Normal Intergration Does Not Require Viral Gene Expression", *J. Virol.*, 63:3822-3828 (1989);
	92	Sanberg *et al.*, XXth Int. Congress of the World Fid. of Hemophilia (1992); **Reference could not be otbained at this time. Will provide a copy at a later date should the Examiner desire a copy.**
	93	Schlehofer *et al.*, "Vaccinia Virus, Herpes Simplex Virus, and Carcinogens Induce DNA Amplification in a Human Cell Line and Support Replication of a Helpervirus Dependent Parvovirus," *Virol.*, 152:110-117 (1986);
	94	Shelling and Smith, "Targeted Integration Of Transfected And Infected Adeno-Associated Virus Vectors Containing The Neomycin Resisitance Gene", *Gene Ther.*, 1:165-169 (1994);
	95	Shigekawa *et al.*, "Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Introduction of Macromolecules into Cells," *BioTechn.*, 6:742-751 (1988);
	96	Snyder, *Current Protocols in Genetics*, Chapter 12, John Wiley and Sons (1997); **Reference could not be otbained at this time. Will provide a copy at a later date should the Examiner desire a copy.**
	97	Thomson *et al.*, "Human Herpesvirus 6 (HHV-6) Is a Helper Virus for Adeno-Associated Virus Type 2 (AAV-2) and the AAV-2 *rep* Gene Homologue in HHV-6 Can Mediate AAV-2 DNA Replication and Regulate Gene Expression," *Virol.*, 204:304-311 (1994);
	98	Toole *et al.*, "Molecular cloning of a cDNA encoding human antihaemophilic factor," *Nature* 312:342-347 (1984);
	99	Uetsuki *et al.*, "Isolation and Characterization of the Human Chromosomal Gene for Polypeptide Chain Elongation Factor-1α," *J. Biol. Chem.*, 264:5791 (1989);
	100	Vehar *et al.*, "Structure of human factor VIII," *Nature* 312:337-342 (1984);
	101	Vincent *et al.* "Replication and Packaging Of HIV Envelope Genes In A Novel Adeno-Associated Virus Vector System," in *Vaccines 90*, pp. 353-359, Cold Spring Harbor Laboratory Press (1990);
	102	Voss *et al.*, "The role of enhancers in the regulation of cell-type-specific transcriptional control," *Trends Biochem. Sci.*, 11:287-289 (1986);
	103	Wood *et al.*, "Expression of active human factor VIII from recombinant DNA clones," *Nature* 312:330-337 (1984);
	104	Yan *et al.*, "Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice," *EMBO J.* 9:869-878 (1990);
	105	Yonemura *et al.*, "Efficient production of recombinant human factor VIII by the expression of their heavy and light chains," *Prot. Engineer.*, 6:669-674 (1993);
	106	Young *et al.*, "Adeno-Associated Virus - an Extreme State of Viral Defectiveness," *Prog. Med. Virol.*, 25:113-132 (1979);
	107	Zhou *et al.*, "Adeno-Associated Virus 2-Mediated High Efficiency Gene Transfer Into Immature And Mature Subsets Of Hematopoietic Progenitor Cells In Human Umbilical Cord Blood", *J. Exp. Med.*, 179:1867-1875 (1994).
	108	Conrad *et al.*, "Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung," *Gene Ther.*, 3: 658-668 (1996)
	109	Byrnes *et al.*, "Immunological Instability of Persistent Adenovirus Vectors in the Brain: Peripheral Exposure to Vector Leads to Renewed Inflammation, Reduced Gene Expression, and Demyelination," *J. Neuroscience* 16: 3045-3055 (1996)
	110	Yang *et al.*, "Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes *in vivo*," *Gene Ther.*, 3: 137-144 (1996)
	111	Yang *et al.*, "Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy," *Proc. Natl. Acad. Sci. USA* 91: 4407-4411 (1994)
	112	Kass-Eisler *et al.*, "The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer," *Gene Ther.*, 1: 395-402 (1994)
	113	Mizuno *et al.*, "Adeno-associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjuction with Ganciclovir Administration," *Jpn. J. Cancer Res.*, 89: 76-80 (1998)
	114	Verma and Somia, "Gene therapy - promises, problems and prospects," *Nature* 389:239-242 (1997)
	115	Kaplitt *et al.*, "Viral Vectors for Gene Delivery and Expression in the CNS," in *Methods: A Companion to Methods in Enzymology* 10: 343-350 (1996)
PL	116	Anderson, "Human gene therapy," *Nature* 392:25-30 (1998)

Examiner: Brian Whiteley	Date Considered: 1/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN-0030	Serial No.: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Linda B. Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

BV	117	Jooss *et al.*, "Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers," *J. Virol.*, 72:4212-4223 (1998)
	118	Rodriguez *et al.*, "DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection Are Rectified by Ubiquitination," *J. Virol.*, 72:5174-5181 (1998)
	119	Szomolanyi-Tsuda *et al.*, "T-Cell-Independent Immunoglobulin G Responses In Vivo Are Elicited by Live-Virus Infection but Not by Immunization with Viral Proteins or Virus-Like Particles," *J. Virol.*, 72:6665-6670 (1998)
	120	Ulmer *et al.*, "Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleoprotein DNA," *J. Virol.*, 72:5648-5653 (1998)
	121	Tsuji *et al.*, "Recombinant Sindbis Viruses Expressing a Cytotoxic T-Lymphocyte Epitope of a Malaria Parasite or of Influenza Virus Elicit Protection against the Corresponding Pathogen in Mice," *J. Virol.*, 72:6907-6910 (1998)
	122	Yauch *et al.*, "Role of Individual T-Cell Epitopes of Theiler's Virus in the Pathogenesis of Demyelination Correlates with the Ability to Induce a Th1 Response," *J. Virol.*, 72:6169-6174 (1998)
BV	123	Xiao *et al.*, "Efficient Lont-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Aden-Associated Virus Vector," *J. Virol.*, 70:8098-8108 (1996)

Examiner: Brinda Rao	Date Considered: 11/8/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Attorney Docket No.: AVIGEN.003C1	Serial No.: Unknown
Applicant: Linda B. Couto *et al.*	
Filing Date: Herewith	Group Art Unit: Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
BL	1	4,965,199	10/23/90	Capon *et al.*			08/07/87
	2	5,843,742	12/01/98	Natsoulis *et al.*			09/08/95
	3	5,872,005	02/16/99	Wang *et al.*			05/12/95
	4	5,219,740	06/15/93	Miller *et al.*			02/13/87
BL	5	5,399,346	03/21/95	Anderson *et al.*			03/30/94
~~BL~~	~~6~~	~~5,255,347~~	~~06/06/93~~ TRO	~~Goldberg *et al.*~~			~~03/19/90~~
BL	7	4,722,848	02/02/88	Paoletti *et al.*			06/19/84
	8	5,436,146	07/25/95	Shenk *et al.*			06/21/93
	9	5,474,935	12/12/95	Chatterjee *et al.*			11/03/93
	10	5,587,308	12/24/96	Carter *et al.*			06/02/92
	11	5,658,785	08/19/97	Johnson			06/06/94
	12	5,861,314	01/19/99	Philip *et al.*			06/06/95
	13	5,693,531	12/02/97	Chiorini *et al.*			11/24/93
	14	5,677,158	10/14/97	Zhou *et al.*			06/07/95
	15	5,252,479	10/12/93	Srivastava			11/08/91
	16	5,580,703	12/03/96	Kotin *et al.*			09/20/94
	17	5,658,776	08/19/97	Flotte *et al.*			06/07/95
BL	18	5,622,856	04/22/97	Natsoulis			08/03/95

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation Yes	Translation No
BL	19	WO 88/09809	12/15/88	~~PCT~~ WIPO				
	20	WO 89/03429	04/20/89	~~PCT~~				
	21	WO 92/03545	03/05/92	~~PCT~~ WIPO				
	22	0 592 836	04/20/94	EP				
	23	WO 96/15777	05/30/96	~~PCT~~ WIPO				
	24	WO 96/13698	05/09/96	PCT				
	25	WO 93/24641	12/09/93	PCT				
	26	WO 95/07995	03/23/95	PCT				
BL	27	WO 94/13788	06/23/94	PCT WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

BL	28	Surosky *et al.*, "Adeno-Associated Virus Rep Proteins Target DNA Sequences to a Unique Locus in the Human Genome," *J. Virol.* 71: 7951-7959 (1997)
	29	Miller and Rosman, "Improved Retroviral Vectors for Gene Transfer and Expression," *BioTechn.* 7: 980-990 (1989)
BL	30	Miller, "Retrovirus Packaging Cells," *Human Gene Ther.* 1: 5-14 (1990)

Examiner: Brian Whitehead Date Considered: 1/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN.003C1	Serial No.: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Linda B. Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

RV	31	Scarpa *et al.*, "Characterization of Recombinant Helper Retroviruses from Moloney-Based Vectors in Ecotropic and Amphotropic Packaging Cell Lines," *Virol.* 180: 849-852 (1991)
	32	Burns *et al.*, "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells," *Proc. Natl. Acad. Sci. USA* 90: 8033-8037 (1993)
	33	Boris-Lawrie and Temin, "Recent advances in retrovirus vector technology," *Curr. Opin. Gen. Dev.* 3: 102-109 (1993)
	34	Haj-Ahmad and Graham, "Development of a Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene," *J. Virol.* 57: 267-274 (1986)
	35	Bett *et al.*, "Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors," *J. Virol.* 67: 5911-5921 (1993)
	36	Mittereder *et al.*, "Evaluation of the Efficacy and Safety of *In Vitro*, Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator cDNA," *Human Gene Ther.* 5: 717-729 (1994)
	37	Seth *et al.*, "Mechanism of Enhancement of DNA Expression Consequent to Cointernalization of a Replication-Deficient Adenovirus and Unmodified Plasmid DNA," *J. Virol.* 68: 933-940 (1994)
	38	Barr *et al.*, "Efficient catheter-mediated gene transfer into the heart using replication-defective adenovirus," *Gene Ther.* 1: 51-58 (1994)
	39	Berkner *et al.*, "Development of Adenovirus Vectors for the Expression of Heterologous Genes," *BioTechn.* 6: 616-629 (1988)
	40	Rich *et al.*, "Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis," *Human Gene Ther.* 4: 461-476 (1993)
	41	Berns and Bohenzyky, "Adeno-associated Viruses: An Update," *Adv. Virus Res.* 32: 243-307 (1987)
	42	Mackett *et al.*, "The Construction and Characterization of Vaccinia Virus Recombinants Expressing Foreign Genes," in *DNA Cloning: A Practical Approach vol. II*, Glover *et al.* (ed.), pp. 191-211, Oxford; New York: IRL Press (1995)
	43	Han *et al.*, "Inhibition of Moloney murine leukemia virus-induced leukemia in transgenic mice expressing antisense RNA complementary to the retroviral packaging sequences," *Proc. Natl. Acad. Sci. USA* 88: 4313-4317 (1991)
	44	Uhlmann and Peyman, "Antisense Oligonucleotides: A New Therapeutic Principle," *Chem. Rev.* 90: 543-584 (1990)
	45	Hélène and Toulmé, "Specific regulation of gene expression by antisense, sense and antigene nucleic acids," *Biochim. Biophys. Acta* 1049: 99-125 (1990)
	46	Agrawal *et al.*, "Oligodeoxynucleoside phosphoroamidates and phosphorothioates as inhibitors of human immunodeficiency virus," *Proc. Acad. Natl. Sci. USA* 85: 7079-7083 (1988)
	47	Heikkila *et al.*, "A c-*myc* antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G_0 to G_1," *Nature* 328: 445-449 (1990)
	48	Samulski *et al.*, "Targeted integration of adeno-associated virus (AAV) into human chromosome 19," *EMBO J.* 10: 3941-3950 (1991)
	49	Kotin *et al.*, "Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination," *EMBO J.* 11: 5071-5078 (1992)
	50	Weiztman *et al.*, "Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA," *Proc. Natl. Acad. Sci. USA* 91: 5808-5812 (1994)
	51	Walz and Schlefor, "Modification of Some Biological Properties of HeLa Cells Containing Adeno-Associated Virus DNA Integrated Into Chromosome 17," *J. Virol.* 66: 2990-3002 (1992)
	52	Hu and Davidson, "The Inducible lac Operator-Repressor System is Functional in Mammalian Cells" *Cell* 48: 555-566 (1987)
	53	Urlaub *et al.*, "Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity," *Proc. Natl. Acad. Sci. USA* 77: 4216-4220 (1980)
	54	Ringold *et al.*, "Co-Expression and Amplification of Dihydroxofolate Reductase cDNA and the *Escherichia coli* XGPRT Gene in Chinese Hamster Ovary Cells," *J. Mol. Appl. Gen.* 1: 165-175 (1981)
RV	55	McVey *et al.*, "Properties of the DNA-Binding Domain of the Simian Virus 40 Large T Antigen," *Mol. Cell. Biol.* 9: 5525-5536 (1989

Examiner: [signature] Date Considered: 1/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN.0031	Serial No.: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Linda B. Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

PV	56	Finney and Bishop, "Predisposition to Neoplastic Transformation Caused by Gene Replacement of H-*ras*1," *Science* 260: 1524-1527 (1993)
	57	Trapnell, "Adenoviral vectors for gene transfer," *Adv. Drug Delivery Rev.* 12: 185-199 (1993)
	58	Michael *et al.*, "Binding-incompetent Adenovirus Facilitates Molecular Conjugate-mediated Gene Transfer by the Receptor-mediated Endocytosis Pathway," *J. Biol. Chem.* 268: 6866-6869 (1993)
	59	Wagner *et al.*, "Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes," *Proc. Natl. Acad. Sci. USA* 89: 6099-6103 (1992)
	60	Mackett *et al.*, "General Method for Production and Selection of Infectious Vaccinia Virus Recombinants Expressing Foreign Genes," *J. Virol.* 49: 857-864 (1984)
	61	Fuerst *et al.*, "Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase," *Proc. Natl. Acad. Sci. USA* 83: 8122-8126 (1986)
	62	O'Gorman *et al.*, "Recombinase-Mediated Gene Activation and Site-Specific Integration in Mammalian Cells," *Science* 251: 1351-1355 (1991)
	63	van Deursen *et al.*, "Cre-mediated site-specific translocation between nonhomologous mouse chromosomes," *Proc. Natl. Acad. Sci. USA* 92: 7376-7380 (1995)
	64	Srivastava *et al.*, "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome," *J. Virol.* 45: 555-564 (1983)
	65	Berns, "Parvovirus Replication," *Microbiol. Rev.* 54: 316-329 (1990)
	66	Ketner *et al.*, "Efficient manipulation of the human adenovirus genome as an infectious yeast artificial chromosome clone," *Proc. Natl. Acad. Sci. USA* 91: 6186-6190 (1994)
	67	Cukor *et al.*, "Biology of Adeno-Associated Virus," in *The Parvoviruses*, Berns (ed.), pp. 33-39, New York, Plenum Press (1984)
	68	Kotin *et al.*, "Site-specific integration by adeno-associated virus," *Proc. Natl. Acad. Sci. USA* 87: 2211-2215 (1990)
	69	Im *et al.*, "The AAV Origin Binding Protein Rep68 is an ATP-Dependent Site-Specific Endonuclease with DNA Helicase Activity," *Cell* 61: 447-457 (1990)
	70	Ghosh and Bachhawat, "Targeting of Liposomes to Hepatocytes," in *Liver Diseases. Targeted Diagnosis and Therapy Using Specific Receptors and Ligands*, Wu *et al.* (eds.), pages 97-103, Marcel Dekker, Inc., New York (1991)
	71	Snyder *et al.*, "Features of the Adeno-Associated Virus Origin Involved in Substrate Recognition by the Viral Rep Protein," *J. Virol.* 67: 6096-6104 (1993)
	72	Chiorini *et al.*, "Biologically Active Rep Proteins of Adeno-Associated Virus Type 2 Produced as Fusion Proteins in *Escherichia coli*," *J. Virol.* 68: 797-804 (1994)
	73	Chiorini *et al.*, "Sequence Requirements for Stable Binding and Function of Rep68 on the Adeno-Associated Virus Type 2 Inverted Terminal Repeats," *J. Virol.* 68: 7448-7457 (1994)
	74	Philip *et al.*, "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," *Mol. Cell. Biol.* 14: 2144-2418 (1994)
	75	Xiao *et al.*, "Adeno-associated virus (AAV) vectors for gene transfer," *Adv. Drug Del. Rev.* 12: 201-215
	76	Page *et al.*, "Recombinant AAV Vectors: Viral and Liposome Mediated Transfection of Recombinant AAV Genome Leads to High Efficiency Gene Transfer into Primary Cells," *J. Cell. Biochem.* Suppl. 18A: 228 (1994)
	77	Nahreini *et al.*, "Cloning and integration of DNA fragments in human cells via the inverted terminal repeats of the adeno-associated virus 2 genome," *Gene* 119: 265-272 (1992)
	78	Srivastava *et al.*, "Construction of a recombinant human parvovirus B19: Adeno-associated virus 2 (AAV) DNA inverted terminal repeats are functional in an AAV-B19 hybrid virus," *Proc. Natl. Acad. Sci. USA* 86: 8078-8082 (1989)
	79	Hermonat and Muzyczka, "Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells," *Proc. Natl. Acad. Sci. USA* 81: 6466-6470 (1984)
	80	McLaughlin *et al.*, "Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures," *J. Virol.* 62: 1963-1973 (1988)
	81	Yang *et al.*, "Characterization of Cell Lines That Inducibly Express the Adeno-Associated Virus Rep Proteins," *J. Virol.* 68: 4847-4856 (1994)
PV	82	Marshall, "Gene Therapy's Growing Pains," *Science* 269: 1050-1055 (1995)

Examiner: BMG N Khatri	Date Considered: 1/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: AVIGEN.0032C1	Serial No.: Unknown
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: Couto *et al.*	
(37 CFR § 1.98(b))		Filing Date: Herewith	Group Art Unit: Unknown

		DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)
BV	1	Connelly *et al.*, "Complete Short-Term Correction of Canine Hemophilia A by In Vivo Gene Therapy," *Blood* 88(10):3846-3853 (1996)
	2	Connelly *et al.*, "Sustained Phenotypic Correction of Murine Hemophilia A by In Vivo Gene Therapy," *Blood* 91(9):3273-3281 (May 1, 1998)
	3	Lozier *et al.*, "Gene Therapy and the Hemophilias," *JAMA* 271(1):47-51 (1994)
	4	Snyder *et al.*, "Persistent and Therapeutic Concentrations of Human Factor IX in Mice after Hepatic Gene Transfer of Recombinant AAV Vectors," *Nature Genetics* 16:270-276 (July 1997)
BV	5	Zatloukal *et al.*, "In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery," *Proc. Natl. Acad. Sci. USA* 91:5148-5152 (1994)

Examiner: [signature] Date Considered: 11/9/02

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.